Teva Pharmaceuticals (@TevaUSA) / Twitter
/cloudfront-us-east-1.images.arcpublishing.com/gray/5ORNVHIZ6FHUHL74IGLVZ6RU4Q.jpg "New York jury holds drug firm Teva liable in opioid crisis")
New York jury holds drug firm Teva liable in opioid crisis
Earnings Preview: It's a mixed bag for Teva Pharma in Q3 | AlphaStreet
Teva Looks Towards a Sustainable Future | AP News
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services | The National Association of Free & Charitable Clinics
Teva Pharmaceuticals, NY reach opioid lawsuit settlements worth $523M - Top Class Actions
Teva Announces Appointment of Richard Francis as President and CEO | Business Wire
Teva Releases Generic EpiPen in Limited Doses in the U.S. - WSJ
Teva: A Complete Overview (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals CEO on the Covid-19 vaccine rollout in Israel
Teva introduces QVAR RediHaler inhalation aerosol in US - Pharmaceutical Technology
We see a stable U.S. market place for our generics, says Teva Pharma CEO
Teva taps former Biogen exec Richard Francis as CEO - News
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare IT News
Acino and Teva sign deal to complete acquisition of Mepha's ...
Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease
Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva Pharmaceuticals (@TevaUSA) / Twitter
Drugmaker Teva latest to settle opioid lawsuits nationally - POLITICO
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Teva Pharmaceuticals Acquisition – PL Developments
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
Teva CEO Schultz likely won't renew employment contract: reports
Teva, with a $4.25B opioid settlement in hand, eyes return to growth by 2027 | Fierce Pharma
Teva Pharmaceuticals (@TevaUSA) / Twitter
Articles with Teva Pharmaceuticals, Inc.
